Details of the Drug

General Information of Drug (ID: DMHTEAO)

Drug Name
Carvedilol
Synonyms
Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [1], [2]
Therapeutic Class
Vasodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 406.5
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.8 mL/min/kg [4]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.4 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.02587 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.3 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.01 mg/mL [3]
Chemical Identifiers
Formula
C24H26N2O4
IUPAC Name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
Canonical SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChIKey
OGHNVEJMJSYVRP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2585
ChEBI ID
CHEBI:3441
CAS Number
72956-09-3
DrugBank ID
DB01136
TTD ID
D0W9LX
VARIDT ID
DR00689
INTEDE ID
DR0282
ACDINA ID
D00103

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor Alpha-1 (ADRA1) TTG28O6 NOUNIPROTAC Antagonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [13]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Carvedilol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [87]
Bepridil DM0RKS4 Moderate Increased risk of cardiac depression by the combination of Carvedilol and Bepridil. Angina pectoris [BA40] [88]
Dronedarone DMA8FS5 Moderate Increased risk of atrioventricular block by the combination of Carvedilol and Dronedarone. Angina pectoris [BA40] [89]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Carvedilol and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [90]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Carvedilol and Cariprazine. Bipolar disorder [6A60] [91]
Talazoparib DM1KS78 Major Decreased clearance of Carvedilol due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [87]
Alpelisib DMEXMYK Moderate Increased metabolism of Carvedilol caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [92]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Carvedilol and Atracurium. Corneal disease [9A76-9A78] [93]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Carvedilol and Mivacurium. Corneal disease [9A76-9A78] [93]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Carvedilol and Pancuronium. Corneal disease [9A76-9A78] [93]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Carvedilol and Pasireotide. Cushing syndrome [5A70] [94]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Carvedilol caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [95]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Carvedilol and OPC-34712. Depression [6A70-6A7Z] [91]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Carvedilol and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [90]
Doxepin DMPI98T Moderate Increased plasma concentrations of Carvedilol and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [96]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Carvedilol when combined with Mepenzolate. Digestive system disease [DE2Z] [87]
Stiripentol DMMSDOY Moderate Decreased metabolism of Carvedilol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Phenobarbital DMXZOCG Moderate Increased metabolism of Carvedilol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Mirabegron DMS1GYT Moderate Decreased metabolism of Carvedilol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [99]
Ripretinib DM958QB Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [100]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Carvedilol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
Aliskiren DM1BV7W Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [94]
Levamlodipine DM92S6N Moderate Increased risk of cardiac depression by the combination of Carvedilol and Levamlodipine. Hypertension [BA00-BA04] [88]
Hydralazine DMU8JGH Minor Decreased metabolism of Carvedilol caused by Hydralazine mediated interference with first-pass metabolism. Hypertension [BA00-BA04] [102]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Carvedilol and Clevidipine butyrate. Hypertension [BA00-BA04] [88]
Belladonna DM2RBWK Moderate Antagonize the effect of Carvedilol when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [87]
Berotralstat DMWA2DZ Major Decreased clearance of Carvedilol due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [103]
Amobarbital DM0GQ8N Moderate Increased metabolism of Carvedilol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [98]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Carvedilol and ITI-007. Insomnia [7A00-7A0Z] [91]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Carvedilol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [87]
PF-06463922 DMKM7EW Moderate Increased metabolism of Carvedilol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [100]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Carvedilol caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [104]
Lumefantrine DM29GAD Moderate Decreased metabolism of Carvedilol caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [100]
GDC-0199 DMH0QKA Major Decreased clearance of Carvedilol due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [100]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Carvedilol caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [105]
Ubrogepant DM749I3 Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Ubrogepant. Migraine [8A80] [106]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Carvedilol due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [94]
Panobinostat DM58WKG Moderate Decreased metabolism of Carvedilol caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [107]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Carvedilol and Siponimod. Multiple sclerosis [8A40] [100]
Fingolimod DM5JVAN Major Increased risk of bradycardia by the combination of Carvedilol and Fingolimod. Multiple sclerosis [8A40] [108]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Carvedilol and Ozanimod. Multiple sclerosis [8A40] [109]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Carvedilol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [87]
Nilotinib DM7HXWT Moderate Decreased metabolism of Carvedilol caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [110]
Rolapitant DM8XP26 Moderate Decreased metabolism of Carvedilol caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [111]
Bupropion DM5PCS7 Moderate Decreased metabolism of Carvedilol caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [112]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Carvedilol caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [113]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Carvedilol and Polythiazide. Oedema [MG29] [114]
S-297995 DM26IH8 Moderate Decreased clearance of Carvedilol due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [87]
Methylscopolamine DM5VWOB Moderate Altered absorption of Carvedilol due to GI dynamics variation caused by Methylscopolamine. Peptic ulcer [DA61] [87]
Lefamulin DME6G97 Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [115]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Carvedilol caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [116]
Relugolix DMK7IWL Major Decreased clearance of Carvedilol due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [117]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Carvedilol and Terazosin. Prostate hyperplasia [GA90] [118]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Carvedilol and Silodosin. Prostate hyperplasia [GA90] [118]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Carvedilol and Levomepromazine. Psychotic disorder [6A20-6A25] [91]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Carvedilol and Quetiapine. Schizophrenia [6A20] [91]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Carvedilol and Aripiprazole. Schizophrenia [6A20] [91]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Carvedilol and Iloperidone. Schizophrenia [6A20] [91]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Carvedilol and Paliperidone. Schizophrenia [6A20] [91]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Carvedilol and Molindone. Schizophrenia [6A20] [91]
Thiothixene DMDINC4 Moderate Increased plasma concentrations of Carvedilol and Thiothixene due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [119]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Carvedilol and Amisulpride. Schizophrenia [6A20] [87]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Carvedilol and Asenapine. Schizophrenia [6A20] [91]
Larotrectinib DM26CQR Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [100]
Docetaxel DMDI269 Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [120]
Taxol DMUOT9V Moderate Decreased clearance of Carvedilol due to the transporter inhibition by Taxol. Solid tumour/cancer [2A00-2F9Z] [120]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Carvedilol and Pipecuronium. Tonus and reflex abnormality [MB47] [93]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Carvedilol and Vecuronium. Tonus and reflex abnormality [MB47] [93]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Carvedilol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [121]
Propafenone DMPIBJK Moderate Decreased metabolism of Carvedilol caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [122]
⏷ Show the Full List of 70 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-galactose E00415 439353 Complexing agent; Flavoring agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sucrose 1,6-distearate E00593 71587490 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Carvedilol 40 mg capsule 40 mg 24 HR Extended Release Oral Capsule Oral
Carvedilol 10 mg capsule 10 mg 24 HR Extended Release Oral Capsule Oral
Carvedilol 80 mg capsule 80 mg 24 HR Extended Release Oral Capsule Oral
Carvedilol 20 mg capsule 20 mg 24 HR Extended Release Oral Capsule Oral
Carvedilol 12.5 mg tablet 12.5 mg Oral Tablet Oral
Carvedilol 25 mg tablet 25 mg Oral Tablet Oral
Carvedilol 3.125 mg tablet 3.125 mg Oral Tablet Oral
Carvedilol 6.25 mg tablet 6.25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 551).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
7 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
8 Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16.
9 In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970-7.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86.
12 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
13 Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study. Med Pharm Rep. 2019 Apr;92(2):158-164.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
32 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
33 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
34 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
35 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
36 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
37 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
38 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
39 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
40 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
41 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
42 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
43 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
44 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
45 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
46 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
47 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
48 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
49 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
50 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
51 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
52 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
53 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
54 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
55 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
56 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
57 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
58 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
59 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
60 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
61 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
62 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
63 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
64 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
65 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
66 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
67 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
68 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
69 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
70 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
71 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
72 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
73 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
74 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
75 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
76 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
77 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
78 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
79 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
80 Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33.
81 Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
82 Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
83 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
84 Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35.
85 Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure. Cas Lek Cesk. 1995 Sep 20;134(18):590-3.
86 Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats. J Biomed Sci. 1996 Apr;3(2):108-116.
87 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
88 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
89 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
90 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
91 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
92 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
93 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
94 Canadian Pharmacists Association.
95 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
96 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
97 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
98 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
99 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
100 Cerner Multum, Inc. "Australian Product Information.".
101 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
102 Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
103 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
104 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
105 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
106 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
107 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
108 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
109 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
110 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
112 Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
113 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
114 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
115 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
116 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
117 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
118 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
119 Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9. [PMID: 7663034]
120 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
121 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
122 Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]